Key result
Low estimated glomerular filtration rate (<60 mL/min) was independently associated with an increased risk of recurrent stroke (HR 1.16; 95% CI 1.04-1.31), which was not mitigated by telmisartan.
Why the study?
Does add-on telmisartan treatment reduce the risk of recurrent stroke in patients with recent ischemic stroke and low eGFR?
Cohort (n=18,666)
Yes
Does add-on telmisartan treatment reduce the risk of recurrent stroke in patients with recent ischemic stroke and low eGFR?
In patients with recent ischemic stroke, low eGFR is independently associated with a higher risk of recurrent stroke, but short-term add-on telmisartan therapy does not mitigate this risk.
Add-on telmisartan should not yet alter management in low-eGFR stroke patients; leaves open whether RAS inhibition mitigates recurrent stroke risk in this subgroup.
BACKGROUND AND PURPOSE: To investigate the association of low estimated glomerular filtration rate (eGFR) <60 mL/min with recurrent stroke risk and to evaluate whether add-on renin-angiotensin system modulator therapy is associated with lower recurrent stroke risk in patients with low eGFR. METHODS: We analyzed the database of a multicenter trial involving 18,666 patients with recent ischemic stroke followed for 2.5 years. Primary outcome was time to first recurrent stroke. Independent associations of low eGFR with outcome in the entire cohort and add-on telmisartan treatment with outcome among those with low eGFR were evaluated. RESULTS: Low eGFR was observed in 3630 (20.1%) patients. Patients with low eGFR were older, more likely women, with a known history of hypertension. In unadjusted analyses, patients with low eGFR were more likely to experience a recurrent stroke (hazard ratio, 1.34; 95% confidence interval, 1.20-1.49). After adjusting for confounders, low eGFR was still associated with recurrent stroke but to a lesser extent (hazard ratio, 1.16; 95% confidence interval, 1.04-1.31). Telmisartan treatment among patients with low eGFR was not independently associated with recurrent stroke (hazard ratio, 1.08; 95% confidence interval, 0.89-1.31). CONCLUSIONS: Low eGFR is independently associated with a higher risk of recurrent stroke, but short-term add-on telmisartan therapy does not seem to mitigate this risk. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00153062.
No takes yet. Share an insight, caveat, or question.
Ovbiagele et al. (2013) conducted a cohort in recent ischemic stroke (n=18,666). Low estimated glomerular filtration rate (<60 mL/min) vs. eGFR ≥60 mL/min was evaluated on time to first recurrent stroke (HR 1.16, 95% CI 1.04-1.31). Low estimated glomerular filtration rate (<60 mL/min) was independently associated with an increased risk of recurrent stroke (HR 1.16; 95% CI 1.04-1.31), which was not mitigated by telmisartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: